Background Relapses can have a major impact on the lives of people with multiple sclerosis (MS), and yet relapse-related healthcare costs have received little attention. This has limited cost-effectiveness analyses of treatments for MS and hampered decision-making regarding the funding of MS healthcare services. Objective To describe health/social care resource use and costs according to the frequency, severity, and endurance of MS relapses. Methods Data from the prospective, longitudinal UK South West Impact of Multiple Sclerosis cohort were used. A total of 11,800 questionnaires from 1441 people with MS were available, including data on relapses, contacts with health/social care professionals, and other MS-related resource use. Results The mean (SD) 6-monthly MS-related health/social care cost for individuals who reported a relapse was £519 (£949), compared to £229 (£366) for those who had not did report a relapse. Care costs varied widely dependent on the characteristics of the relapse. The mean (SD) cost when a relapse was not treated with steroids was £381 (£780), whilst the equivalent cost was £3579 (£1727) when a relapse resulted in hospitalization. Conclusions The impact of relapses on health and social care resources and costs differs according to their frequency, length, and severity. The data provided here can be used in cost-effectiveness analyses and to inform decisionmaking regarding healthcare provision for people with this condition.
Introduction
Multiple sclerosis (MS) is a chronic, disabling neurological disorder that can affect any system of the body. It is one of the commonest global causes of neurological disability in young and middle-aged adults [1, 2] , with a worldwide prevalence of approximately 33 per 100,000 population [3] . The economic impact of MS is substantial. In surveys of nine European countries, Kobelt et al. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] estimated the societal costs of MS to be in the region of €18,000-€62,000 per patient per year, and in the UK, MS has been estimated to cost £1.4 billion per annum to the NHS and society [14] .
Over the past 15-20 years, health economic analyses of treatments for people with MS have received much attention in health policy contexts [15] [16] [17] , and it is widely accepted that data available to inform the assessment of the costeffectiveness of treatments for MS are sparse and uncertain [18] [19] [20] [21] [22] . There is limited empirical evidence on the costs of health and social care for people with MS [18] , with a particular lack of detail regarding resource use and costs relating to the relapses experienced by people with MS.
Relapses can have a major impact on the lives of people with MS [23] . Approximately 85 % of people when first diagnosed with MS are diagnosed with relapsing-remitting MS (RRMS) [24] . Their disease course is characterized by episodes when they are well and episodes, known as relapses, when they experience an acute exacerbation of existing symptoms or new symptoms [25, 26] . Relapses vary widely in their presentation, involving a single symptom occurring over a few hours, or a wide range of neurological dysfunction developing over days or weeks [25] ; relapse frequency is highly variable [27] ; relapses ordinarily occur unexpectedly with the length of the gap between attacks being unpredictable; there is a range of severity of symptoms experienced and; there are differences in terms of the length of episodes.
Research to date on the costs of care relating to relapses [10, 13, [28] [29] [30] [31] [32] [33] has been characterized by having considered their impact over different time periods, in a number of cases being based on small samples [31] [32] [33] , and has provided little detail about the nature of the relapses themselves [10, 28, 32, 33] . A recent systematic review of the economic burden of MS [34] concluded that, based on currently available information, the resource implications associated with relapses cannot be accurately estimated, and that further work is required to determine their economic impact [35] .
The aim of the current study was to describe health and social care resource use and costs according to the frequency, severity, and endurance of relapses experienced by people with MS, based on data from a UK longitudinal, cohort study.
Methods
The South West Impact of Multiple Sclerosis (SWIMS) project Data from the UK South West Impact of Multiple Sclerosis (SWIMS) project [36] were used for analysis. SWIMS is a longitudinal, prospective cohort study of people with MS in Devon and Cornwall (South West England), with individuals followed up every 6 months. Full details of the project methods have been reported elsewhere [36] . Data are collected on demographics and clinical characteristics, and on a range of self-report health and social care resource use items pertaining to MS. SWIMS commenced recruitment in August 2004, and data from all participants who had completed baseline questionnaires at October 2012 were included in this analysis.
The study was approved in the UK by the Cornwall and Plymouth and South Devon Research Ethics Committees, and written informed consent obtained from all participants.
Measures

Clinical characteristics
Participants reported the type of MS they had and the length of time since their diagnosis. Disease severity was assessed by clinician-reported Expanded Disability Status Scale (EDSS) [37] scores collected during routine clinic visits. These were matched with resource use data if recorded within the same 3-month window.
Relapse characteristics and associated resource use
For the previous 6 months, participants reported whether they had experienced a relapse, the number experienced, their length, whether they had been admitted to hospital as a result, and if they had been treated with oral and/or intravenous steroids. They were asked to give these details for up to four relapses in the 6-month period (at recruitment, this information was reported for the previous 12 months).
Health/social care resource use Participants reported whether they had seen the following health or social care professionals in the previous 6 months in relation to their MS, and the number of times that they had seen them: chiropodist, clinical psychologist, continence advisor, district nurse, dietician, GP, MS specialist nurse, neurologist, occupational therapist, ophthalmologist, physiotherapist, rehabilitation doctor, social worker, speech therapist. In addition, they stated whether they had had contact with a pain management service and/or a rehabilitation/respite service, including their frequency of contact. Frequency of contact was categorized as: 'not seen', '1 time', '2-4 times', and '5 or more times'. For the purposes of analysis, these frequency categories were assigned values of 0, 1, 3 and 5, respectively.
Valuation
Service use was costed at 2012 costs using UK nationally recognized unit costs of health and social care resource items. The sources used were from the Personal Social Services Research Unit [38] , NHS Reference Costs [39] , and the British National Formulary [40] , and are detailed in Table 1 .
Data analyses
The demographic and clinical characteristics of the SWIMS sample were described at recruitment, and were compared for representativeness with other samples of people with MS in the UK.
For each 6-month follow-up period, the number and percentage of responses which described use of each of the health/social care resources in relation to MS were calculated, as was the mean (SD) number of contacts. Unit costs were applied to resource use data on a per response basis, and mean (SD) costs for each item were determined.
Descriptive data are presented on the mean (SD) disaggregated health/social care resource use item costs relating to MS for respondents by relapse status. In addition, descriptive statistics are estimated for the mean (SD) 6-monthly costs of MS health/social care according to the features of relapses reported: number of relapses, severity, and endurance. Mean (SD) costs of care of those who reported at least one relapse were estimated by EDSS stages.
Data management was conducted in Excel 2007 and STATA 12.1, and all data analyses were conducted in STATA 12.1, with data defined as panel data using the xt commands.
Results
Description of the sample and data
As of October 2012, 11,800 questionnaires were available from 1441 people with MS. These were completed between 10th September 2004 and 4th October 2012. Respondents provided a mean (SD) of 8 (4) questionnaires, with a range from 1 to 17. The demographic and clinical features of participants on recruitment to SWIMS are given in Table 2 . [41] [42] [43] [44] [45] [46] [47] . In addition, the relapse rates in the SWIMS sample (1.1 a year) were very similar to those estimated in prospective evaluations of relapses (0.5-1 year) [27] .
Six-monthly relapse-related health/social care resource use and costs of care
At follow-up, 1300 people gave 10,075 responses to the question of whether they had experienced a relapse in the past 6 months. A total of 5457 (54.2 %) responses indicated that participants had not experienced a relapse, 1501 (14.9 %) answers indicated that respondents did not know whether they had had a relapse or not, and 3117 (30.9 %) indicated that they had experienced at least one relapse. Not reported (n = 41) Table 3 presents mean (SD) costs of health/social care resource use in relation to MS in the previous 6 months for the group of responses that reported experiencing a relapse in the previous 6 months (n = 3117 responses) and the group of responses which reported not experiencing a relapse in the previous 6 months (n = 5457 responses). Disaggregated mean (SD) 6-monthly resource use and costs of care are also given in Table 3 for those who had had a relapse and those who had not.
The main differences between those who reported a relapse and those who did not related to whether participants had seen a clinical psychologist, a GP, a neurologist, and a MS specialist nurse, and whether they had been in contact with a pain management service. The percentage of respondents who had been in contact with each of these services was greater for the group who had experienced a relapse. This was also reflected in the higher mean (SD) costs for these individual resource items. The general profile across the resource items was one of greater resource use and costs of care for those who had had a relapse, as demonstrated by the higher mean (SD) total cost in the relapse group of £519 (£949) as compared to £229 (£366) for the group who had not experienced a relapse. The most costly resource item used by people who reported a relapse was admission to hospital. This was followed by seeing a neurologist, a GP, and stays in a rehabilitation/ respite unit. Table 4 and Fig. 1 present mean (SD) 6-monthly health/social care costs associated with MS for respondents according to the number of relapses they reported during this time period. These figures indicate that the number of relapses experienced per se does not appear to be a strong driver of resource use costs.
Frequency of relapses
Relapse severity Table 4 and Fig. 1 present mean (SD) 6-monthly costs of care according to the severity of the relapses reported. The figures show greater costs for more severe relapses, from those that 'limited everyday activities' to those that resulted in admission to hospital. By far the greatest mean (SD) health/social care costs were for 6-month periods in which there was an admission to hospital as a result of the relapse [£3579 (£1727)], with multiple admissions resulting in increased costs. For example, the mean (SD) costs of care for a 6-month period were approximately £6348 (£2663) if the respondent had been admitted to hospital for two relapses. 
Relapse length
There was a clear relationship between the length of the relapse and the costs of 6-monthly MS-related health/social care resources (Table 4 ; Fig. 1) . Relapses lasting about 48 h were associated with mean (SD) costs of £329 (£901), whilst respondents experiencing a relapse which lasted longer than 1 month had mean (SD) costs of £808 (£1186).
Relapses in relation to disease severity (EDSS)
The relationship between disease severity, according to the EDSS, and the costs of care for those reporting a relapse is presented in Table 4 . This indicates a reduction in costs of health/social care from EDSS 0 to EDSS 3, followed by increasing costs in the more severe health states (from EDSS 4 to EDSS 8).
Discussion
This paper presents new, disaggregated data on the health/social care resources used by people with multiple sclerosis in relation to relapses, with estimates of costs given for a detailed breakdown of the particular characteristics of relapses experienced.
The findings indicate that the mean (SD) health/social care cost for an individual with MS who has experienced a relapse in the previous 6 months is approximately £519 (£949). The data presented here provide important insights on the wide variability in costs associated with relapses, and that the precision of these costs can be improved if the particular characteristics of the relapses experienced are considered. For example, 6-monthly costs of care were a mean (SD) of £381 (£780) if the relapse was not treated with steroids, £634 (£1146) if four relapses were experienced, £808 (£1186) if the relapse lasted longer the 1 month, and £3579 (£1727) if there was an admission to hospital due to the relapse.
That costs of care are highly variable dependent on the particular characteristics of the relapse experienced, may account for some of the disparity in previously reported relapse costs. For example, in the UK, Kobelt et al. [10] have given a mean relapse cost of £561, whilst Parkin et al. [32] have reported a mean estimate of £2115. However, it must be considered that these figures are not directly comparable with the estimates from the SWIMS data, as different items of health/social care resource use were included.
In addition, the methods for estimating relapse costs have differed in the few studies that have considered them. The most common approach has been to: (1) calculate resource use costs of those who do not report a relapse in a specified time period; (2) calculate resource use costs of those who do report a relapse in the same specified time period and; (3) subtract the former from the latter [31] [32] [33] 48] . The resulting relapse cost estimate is therefore timedependent (e.g., the cost of a relapse over 6 months, or the cost of a relapse over 3 months). This methodology means that relapse costs for different time periods must be considered as such, rather than simply being defined as a 'relapse cost'.
O'Brien et al. [30] have approached costing relapses differently. They identified people with MS who had experienced a relapse, determined their resource use that was specifically associated with the relapse (not the time period containing the relapse e.g., 6 months), and estimated the cost for this resource use. This raises the difficulty of defining what is, and what is not, due to a relapse, and over what period of time the consequences of a relapse in terms of resource use should be considered. The methodological hallmark of O'Brien et al.'s research is that the authors did not define a relapse as a single entity. They recognized the variability in the severity of relapses by categorizing them as high intensity (hospitalization and subsequent care), medium intensity (acute treatment, e.g., intravenous steroids in outpatient or home setting), and low intensity (physician office visits and symptom-related medications) and costing them separately and accordingly. The SWIMS analysis, although having taken the 'time-dependent' approach described in the previous paragraph, builds on O'Brien et al.'s foundation by considering the costs of care of relapses in terms of their frequency, their endurance, and their severity.
The descriptive results described here suggest that costs of health/social care resource use do not consistently increase in line with the number of relapses that an individual has experienced in the previous 6 months. This may imply that the number of relapses per se has a limited impact on resource use, with length and severity of relapses being of greater relevance. Increased understanding of the nature and experience of relapses [25] , and the future use of regression analysis should help to disentangle this hypothesis.
Costs of health/social care reduce from EDSS 0 to EDSS 3 before gradually rising from then on as disability increases, until a substantial increase from EDSS 7 to EDSS 8 (although it should be noted that the sample at EDSS 8 is small). This may be reflective of an initial flurry of contacts and resource use around the time of diagnosis, followed by a period of stabilization during which resource use is less concentrated. Increased contact may then occur as MS deteriorates, particularly as walking impairments become evident from EDSS 4 onwards and further services and support are established.
Strengths and limitations of the study
The research described here is focused on a NHS/social care perspective (although medication costs, other than relapse-related steroids are not included). It does not account for a wider societal (or care-giver) perspective (e.g., informal care, productivity losses). As such, it does not identify the full economic impact of MS. This was not the intention of the study, but should be considered when assessing or using the costs presented.
The response format of the study questionnaire (which was pre-set) meant that respondents could report that they had seen each health/social care professional a maximum of '5? times' in a 6-month period. For the purposes of analysis, such a response was assigned a conservative frequency of five occasions. This may well mean that the reported costs underestimate the true cost of health/social care resource use, and should be reflected when the figures are utilized.
Of the EDSS scores available, 2152, from 664 respondents, were reported within a 3-month window of a SWIMS questionnaire being completed. The demographic and clinical characteristics of this sub-group were compared at recruitment with the remainder of the sample. There were no statistically significant differences between those with and without EDSS scores in terms of gender, type of MS, having experienced a relapse, or the number of relapses, in the previous 12 months.
A key strength of this research is that the findings are based on a prospective, longitudinal cohort study, with very high response rates [23] , and a resulting sample that appears representative of people with MS in the UK [41] [42] [43] [44] [45] [46] [47] . This minimizes the possibility of selection and response bias in the estimates of resource use and costs, and implies the generalizability of the findings to other people with MS. This marks a departure, and advance, from previous research in this area, which has been characterized by cross-sectional surveys, sent out via patient associations with some resulting low response rates (e.g., [10, 48] ). The detailed breakdown of resource use and costs in relation to particular characteristics of relapses is a clear development from previous research, which has tended to take a generalized view of relapses when costing these events. The data available provide opportunities for further analyses using statistical techniques, and to develop hypotheses around the resource use associated with relapses. However, given the high-quality data available from SWIMS, and the reported generalizability of SWIMS participants, descriptive statistics are given in the present analyses to provide the data in a simple format for use and interpretation by others. Regression-based analyses are a recommendation for future research.
Conclusions
This research highlights the need for data on the resource use and costs of health/social care of people with MS to be presented in a clear, disaggregated manner. Only by such an approach can 'like with like' comparisons be drawn over time, across countries, and based on individual clinical characteristics. The over-aggregation of information may lead to important relationships or distinctions being masked and missed.
Consistency in the methods used to cost relapses is needed. This should be founded on the understanding that relapses can be quite different across and within individuals over time, varying in frequency, length and severity. Further research is necessary to appropriately cost relapses according to their particular features.
The data presented here, from a representative sample of people with MS in the UK, can be used to start to improve the validity of resource use and cost information relating to relapses. This, in turn, can inform the decision-making process regarding the cost-effectiveness of MS treatments and health and social care provision for people with MS.
